Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Tags › Posts tagged Pharmaceutical Industry

Tag: Pharmaceutical Industry

Agency has approved three competitors, but doesn't regulate prices, official says. (AP Photo/Jose Luis Magana) Healthcare

FDA defends itself from EpiPen critics

Robert King · September 14, 2016 4:53 pm
The House Oversight Committee's Sept. 21 hearing will include testimony from Mylan CEO Heather Bresch on the high price tag of $600 for EpiPens. (iStock photo) Healthcare

House panel to hold hearing over EpiPen price hikes

Robert King · September 14, 2016 1:50 pm
Sen. Chuck Grassley blasted Mylan for insufficient answers to a series of questions he gave the drug maker about the EpiPen price hike. (AP Photo/J. Scott Applewhite) Healthcare

Do better, Grassley tells EpiPen maker

Robert King · September 9, 2016 6:51 pm
Costly new drugs do extend the lives of patients significantly, a new study finds. (iStock Photo) Healthcare

Study: Expensive cancer drugs are worth it

Paige Winfield Cunningham · September 7, 2016 8:00 pm
The Permanent Subcommittee on Investigations will look into Mylan's pricing and competition practices. (AP Photo/Alex Brandon) Healthcare

Senate starts investigation into EpiPen price hikes

Robert King · September 7, 2016 7:31 pm
Democratic presidential candidate Hillary Clinton said the recent news that EpiPen maker Mylan hiked prices by 500 percent shows the government needs stronger tools to crack down on pharmaceutical companies. (AP Photo/Carolyn Kaster) Healthcare

Clinton plan goes after price-hiking drug makers

Paige Winfield Cunningham · September 2, 2016 2:02 pm
The goal is to raise the price just enough to appease the public as well as shareholders. (GOP Arcade) Healthcare

EpiPen outrage fuels video game

Robert King · August 31, 2016 8:56 pm
Mixing opioids with antidepressants such as Xanax can make breathing difficult, an agency review found. (iStock Photo) Healthcare

FDA: Mixing pain and anxiety drugs can kill you

Robert King · August 31, 2016 5:27 pm
The letter from Sens. Amy Klobuchar, D-Minn., Chuck Grassley, R-Iowa, and Richard Blumenthal, D-Conn., also delves into the impact on other healthcare programs. (AP Photos) Healthcare

Senators probe impact of EpiPen price on Medicare, Medicaid

Robert King · August 31, 2016 3:33 pm
Eight-page letter shows much skepticism over Mylan's move to sell a cheaper version of the allergy shot. (AP Photo/Rich Pedroncelli, File) Healthcare

Senate Dems launch expansive probe on EpiPen pricing

Robert King · August 30, 2016 3:48 pm
"While families and schools are struggling to keep up with your company's unreasonable price increases, Mylan has profited richly from its pricing strategy," said a letter from committee Chairman Jason Chaffetz, R-Utah, and Rep. Elijah Cummings of Maryland, the top Democrat on the panel. (AP Photo/J. Scott Applewhite) Healthcare

House panel wants Mylan to answer for EpiPen

Robert King · August 29, 2016 7:01 pm
"Improving the generic drug review process will promote competition and ultimately lower the cost of prescription drugs for America's patients," according to the letter. (Wikimedia Commons) Healthcare

House Republicans slam FDA on EpiPen price hikes

Robert King · August 29, 2016 4:59 pm
Advertisement
  • ‹Previous page
  • 1
  • …
  • 109
  • 110
  • 111
  • 112
  • 113
  • …
  • 142
  • ›Next page
Page 111 of 142
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement